Regeneron Pharmaceuticals Inc
I · Analyse IA
En bref
Regeneron discovers and commercializes medicines for eye diseases (EYLEA for macular degeneration), allergic conditions (Dupixent for eczema and asthma), cancer (Libtayo), and rare diseases [Yahoo Finance]. The company operates through a combination of selling FDA-approved drugs and investing heavily in research partnerships to develop next-generation treatments using technologies like gene-editing and radiopharmaceuticals [Yahoo Finance].
Regeneron Pharmaceuticals is a major biotechnology company that develops treatments for eye diseases, cancer, and rare conditions, generating $14,3B in annual revenue [Yahoo Finance]. The company recently suffered a significant setback when its experimental melanoma drug combination failed in late-stage testing, causing the stock to drop sharply [Yahoo Finance]. Despite this disappointment, Regeneron maintains a strong financial position with $4,1B in free cash flow and continues expanding through partnerships in gene-editing and oncology research [Yahoo Finance].
Regeneron is financially robust with exceptional profitability and zero net debt.
Score Sentinellis
8,9/10
En bonne santé financière
Capitalisation boursière
$66,1B
Chiffre d'affaires (12 mois)
$14,3B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
6 articles · classés par pertinence
- Macro2026-05-20
Why Regeneron (REGN) Shares Are Trading Lower Today
Yahoo Finance
- Macro2026-05-19
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal
Yahoo Finance
- Macro2026-05-19
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Yahoo Finance
- Macro2026-05-19
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
Yahoo Finance
- Macro2026-05-19
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback
Simply Wall St
- Macro2026-05-18
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Yahoo Finance
Premium · gratuit avec tout compte
Pipeline concentration risk: The melanoma trial failure exposed Regeneron's dependence on successful late-stage trials to maintain growth, and further setbacks in other pipeline programs could significantly impact future revenue [Yahoo Finance]
Risques
4
Opportunités
5
Signaux d'alerte
3
Direction
10
11 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Regeneron Pharmaceuticals Inc
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 5 opportunités et 3 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?